Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 3
1988 4
1989 3
1990 1
1991 1
1992 4
1993 7
1994 8
1995 6
1996 7
1997 11
1998 9
1999 6
2000 6
2001 6
2002 2
2003 7
2004 1
2005 1
2006 4
2007 4
2008 8
2009 4
2010 3
2011 4
2012 5
2013 5
2014 3
2015 2
2016 2
2017 2
2018 4
2019 3
2020 1
2021 1
2022 2
2023 1
2024 4
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

153 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Intranasal Azelastine and Fluticasone as Combination Therapy for Allergic Rhinitis: Systematic Review and Meta-analysis.
Debbaneh PM, Bareiss AK, Wise SK, McCoul ED. Debbaneh PM, et al. Otolaryngol Head Neck Surg. 2019 Sep;161(3):412-418. doi: 10.1177/0194599819841883. Epub 2019 Apr 9. Otolaryngol Head Neck Surg. 2019. PMID: 30961435
OBJECTIVE: Combination therapy with intranasal azelastine and fluticasone propionate is an option for treatment of allergic rhinitis. This systematic review and meta-analysis examines existing literature to determine efficacy in treating allergic rhinitis compared to monot …
OBJECTIVE: Combination therapy with intranasal azelastine and fluticasone propionate is an option for treatment of allergic rhinitis. …
Intranasal antihistamines and corticosteroids in allergic rhinitis: A systematic review and meta-analysis.
Sousa-Pinto B, Vieira RJ, Brozek J, Cardoso-Fernandes A, Lourenço-Silva N, Ferreira-da-Silva R, Ferreira A, Gil-Mata S, Bedbrook A, Klimek L, Fonseca JA, Zuberbier T, Schünemann HJ, Bousquet J. Sousa-Pinto B, et al. J Allergy Clin Immunol. 2024 Aug;154(2):340-354. doi: 10.1016/j.jaci.2024.04.016. Epub 2024 Apr 27. J Allergy Clin Immunol. 2024. PMID: 38685482 Free article. Review.
Both in perennial and seasonal AR, most assessed treatments were more effective than placebo. In seasonal AR, azelastine-fluticasone, fluticasone furoate, and fluticasone propionate were the medications with the highest probability of resulting in moderate or large improve …
Both in perennial and seasonal AR, most assessed treatments were more effective than placebo. In seasonal AR, azelastine-fluticasone, …
Second-generation antihistamines: a comparative review.
Slater JW, Zechnich AD, Haxby DG. Slater JW, et al. Drugs. 1999 Jan;57(1):31-47. doi: 10.2165/00003495-199957010-00004. Drugs. 1999. PMID: 9951950
This article evaluates second-generation antihistamines, including acrivastine, astemizole, azelastine, cetirizine, ebastine, fexofenadine, ketotifen, loratadine, mizolastine and terfenadine, for significant features that affect choice. ...
This article evaluates second-generation antihistamines, including acrivastine, astemizole, azelastine, cetirizine, ebastine, fexofen …
Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients.
Klussmann JP, Grosheva M, Meiser P, Lehmann C, Nagy E, Szijártó V, Nagy G, Konrat R, Flegel M, Holzer F, Groß D, Steinmetz C, Scherer B, Gruell H, Schlotz M, Klein F, de Aragão PA, Morr H, Al Saleh H, Bilstein A, Russo B, Müller-Scholtz S, Acikel C, Sahin H, Werkhäuser N, Allekotte S, Mösges R. Klussmann JP, et al. Sci Rep. 2023 Apr 26;13(1):6839. doi: 10.1038/s41598-023-32546-z. Sci Rep. 2023. PMID: 37100830 Free PMC article. Clinical Trial.
Ninety SARS-CoV-2 positive patients were randomized into 3 groups receiving placebo, 0.02% or 0.1% azelastine nasal spray for 11 days, during which viral loads were assessed by quantitative PCR. ...Comparable numbers of adverse events occurred in all treatment groups with …
Ninety SARS-CoV-2 positive patients were randomized into 3 groups receiving placebo, 0.02% or 0.1% azelastine nasal spray for 11 days …
Azelastine Nasal Spray in Non-Hospitalized Subjects with Mild COVID-19 Infection: A Randomized Placebo-Controlled, Parallel-Group, Multicentric, Phase II Clinical Trial.
Meiser P, Flegel M, Holzer F, Groß D, Steinmetz C, Scherer B, Jain R, Carvin-Ii Study Group. Meiser P, et al. Viruses. 2024 Dec 13;16(12):1914. doi: 10.3390/v16121914. Viruses. 2024. PMID: 39772221 Free PMC article. Clinical Trial.
A total of 39 (32.0%) subjects in the azelastine 0.1% treatment group and 40 (31.0%) subjects in the placebo group reported 48 and 51 adverse events, respectively. It is therefore concluded that azelastine 0.1% nasal spray is an efficacious, safe, and well-tolerated …
A total of 39 (32.0%) subjects in the azelastine 0.1% treatment group and 40 (31.0%) subjects in the placebo group reported 48 and 51 …
Azelastine nasal spray in the management of seasonal allergic rhinitis.
Meltzer EO, Weiler JM, Dockhorn RJ, Widlitz MD, Freitag JJ. Meltzer EO, et al. Ann Allergy. 1994 Apr;72(4):354-9. Ann Allergy. 1994. PMID: 7908778 Clinical Trial.
Azelastine is capable of inhibiting both early-phase and late-phase allergic responses in animals and humans. ...Seventy-three percent of the patients treated with azelastine reported overall improvement upon global assessment of their symptoms. Adverse effects with …
Azelastine is capable of inhibiting both early-phase and late-phase allergic responses in animals and humans. ...Seventy-three percen …
Comparison of azelastine and chlorpheniramine in the treatment of mastocytosis.
Friedman BS, Santiago ML, Berkebile C, Metcalfe DD. Friedman BS, et al. J Allergy Clin Immunol. 1993 Oct;92(4):520-6. doi: 10.1016/0091-6749(93)90076-r. J Allergy Clin Immunol. 1993. PMID: 8104966 Clinical Trial.
RESULTS: Subjects' mean wheal area responses provoked by histamine or morphine sulfate were significantly lowered by azelastine when compared with chlorpheniramine. Plasma histamine levels in subjects receiving azelastine or chlorpheniramine were not significantly d …
RESULTS: Subjects' mean wheal area responses provoked by histamine or morphine sulfate were significantly lowered by azelastine when …
Efficacy and safety of intranasal medications for allergic rhinitis: Network meta-analysis.
Sousa-Pinto B, Vieira RJ, Bognanni A, Gil-Mata S, Ferreira-da-Silva R, Ferreira A, Cardoso-Fernandes A, Ferreira-Cardoso H, Marques-Cruz M, Duarte VH, Castro-Teles J, Campos-Lopes M, Teixeira-Ferreira A, Lourenço-Silva N, Chérrez-Ojeda I, Bedbrook A, Klimek L, Nuñez JJY, Zuberbier T, Fonseca JA, Schünemann HJ, Bousquet J; ARIA 2024 guideline panel. Sousa-Pinto B, et al. Allergy. 2025 Jan;80(1):94-105. doi: 10.1111/all.16384. Epub 2024 Nov 16. Allergy. 2025. PMID: 39548801 Review.
RESULTS: We included 167 primary studies, most of which assessed patients with seasonal AR. Among individual medications, azelastine-fluticasone, and fluticasone furoate were the most frequently highest-ranked interventions for efficacy outcomes, being regularly associated …
RESULTS: We included 167 primary studies, most of which assessed patients with seasonal AR. Among individual medications, azelastine- …
Azelastine eye drops in the treatment of perennial allergic conjunctivitis.
Nazarov O, Petzold U, Haase H, Nguyen DT, Ellers-Lenz B, Hermann R. Nazarov O, et al. Arzneimittelforschung. 2003;53(3):167-73. doi: 10.1055/s-0031-1297090. Arzneimittelforschung. 2003. PMID: 12705171 Clinical Trial.
Azelastine significantly improved itching and conjunctival redness versus placebo (p < 0.001). ...On Day 7, ocular symptoms score improved by 1.5 +/- 0.9 (versus 0.5 +/- 0.8 placebo) with score improvement > or = 2 in 55% with azelastine (versus 14% placebo). …
Azelastine significantly improved itching and conjunctival redness versus placebo (p < 0.001). ...On Day 7, ocular symptoms score …
Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity.
Ciprandi G, Buscaglia S, Catrullo A, Pesce G, Fiorino N, Montagna P, Bagnasco M, Canonica GW. Ciprandi G, et al. Clin Exp Allergy. 1997 Feb;27(2):182-91. Clin Exp Allergy. 1997. PMID: 9061218 Clinical Trial.
We have recently demonstrated that nasal azelastine inhibits the clinical and inflammatory events following nasal allergen challenge. ...The former investigated the onset of effect of a single dose of azelastine eye drops administered 20 min after clinical response …
We have recently demonstrated that nasal azelastine inhibits the clinical and inflammatory events following nasal allergen challenge. …
153 results

Searches related to "azelastine"